Department of Infectious Disease, The First Hospital Affiliated with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, P.R. China.
Department of Infectious Disease, The First Hospital Affiliated with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, P.R. China.
Int J Mol Med. 2022 Sep;50(3). doi: 10.3892/ijmm.2022.5174. Epub 2022 Jul 20.
Severe fever with thrombocytopenia syndrome (SFTS) has been acknowledged as an emerging infectious disease that is caused by the SFTS virus (SFTSV). The main clinical features of SFTS on presentation include fever, thrombocytopenia, leukocytopenia and gastrointestinal symptoms. The mortality rate is estimated to range between 5‑30% in East Asia. However, SFTSV infection is increasing on an annual basis globally and is becoming a public health problem. The transmission cycle of SFTSV remains poorly understood, which is compounded by the pathogenesis of SFTS not being fully elucidated. Since the mechanism underlying the host immune response towards SFTSV is also unclear, there are no effective vaccines or specific therapeutic agents against SFTS, with supportive care being the only realistic option. Therefore, it is now crucial to understand all aspects of the host‑virus interaction following SFTSV infection, including the antiviral states and viral evasion mechanisms. In the present review, recent research progress into the possible host immune responses against SFTSV was summarized, which may be useful in designing novel therapeutics against SFTS.
严重发热伴血小板减少综合征（SFTS）已被确认为一种新发传染病，由 SFTS 病毒（SFTSV）引起。SFTS 的主要临床特征包括发热、血小板减少、白细胞减少和胃肠道症状。在东亚，其死亡率估计在 5%-30%之间。然而，SFTSV 感染在全球范围内呈逐年上升趋势，已成为一个公共卫生问题。SFTSV 的传播周期仍知之甚少，SFTS 的发病机制也尚未完全阐明。由于宿主对 SFTSV 免疫反应的机制尚不清楚，因此目前尚无针对 SFTS 的有效疫苗或特效治疗药物，只能采取支持性治疗。因此，了解 SFTSV 感染后宿主-病毒相互作用的各个方面，包括抗病毒状态和病毒逃逸机制，现在至关重要。本综述总结了宿主针对 SFTSV 可能产生的免疫反应的最新研究进展，这可能有助于设计针对 SFTS 的新型治疗方法。
